Convidecia Air (Ad5-nCoV-IH) / CanSino - LARVOL DELTA

Safety, efficacy and immunogenicity of aerosolized Ad5-nCoV COVID-19 vaccine in a non-inferiority randomized controlled trial. (PubMed, NPJ Vaccines) - P3 | "Participants were randomized 1:1 to receive either one dose of inhaled Recombinant COVID-19 Vaccine (Ad5-nCoV-IH) or intramuscular tozinameran (BNT-IM)...Both vaccines had comparable efficacy against COVID-19 variants. This study was funded by Tianjin Biomedical Science and Technology Major Project."

Head-to-Head • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial. (PubMed, Emerg Microbes Infect) - "The seroconversion rates of neutralizing antibodies against BA.1 in Ad5-nCoVO-IH, Ad5-nCoV/O-IH, and Ad5-nCoV-IH groups were 56.00%, 59.60% and 48.67% with no significant difference among the groups. Overall, the investigational vaccines were demonstrated to be safe and well tolerated in adults, and was highly effective in inducing mucosal immunities in addition to humoral and cellular immune responses defending against SARS-CoV-2 variants.Trial registration: Chictr.org identifier: ChiCTR2200063996."

Clinical • Journal • Cough • Fatigue • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain • Respiratory Diseases • Xerostomia

Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE) (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: CanSino Biologics Inc. | N=13000 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (clinicaltrials.gov) - P3 | N=0 | Withdrawn | Sponsor: CanSino Biologics Inc. | N=1350 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease

IH Convidecia as Second Booster Dose Against Breakthrough Infections (clinicaltrials.gov) - P3 | N=540 | Completed | Sponsor: CanSino Biologics Inc. | Active, not recruiting ➔ Completed

Trial completion • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents (clinicaltrials.gov) - P3 | N=91 | Terminated | Sponsor: CanSino Biologics Inc. | N=1000 ➔ 91 | Trial completion date: Aug 2023 ➔ Jan 2023 | Recruiting ➔ Terminated | Trial primary completion date: May 2023 ➔ Jan 2023; Difficulty recruiting subjects, so the study was terminated.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

IH Convidecia as Second Booster Dose Against Breakthrough Infections (clinicaltrials.gov) - P3 | N=540 | Active, not recruiting | Sponsor: CanSino Biologics Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Viral vector • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (clinicaltrials.gov) - P3 | N=1350 | Not yet recruiting | Sponsor: CanSino Biologics Inc. | Trial completion date: Mar 2023 ➔ Jun 2023 | Initiation date: Aug 2022 ➔ Nov 2022 | Trial primary completion date: Nov 2022 ➔ Mar 2023

Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Immunogenicity, Efficacy and Safety of Inhaled (IH) Viral Vectored Vaccine (Convidecia, CanSino) as Second Booster Dose Against Emerging Variants of Concern (VOC) (clinicaltrials.gov) - P3 | N=540 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Solid Tumor

A Study to Evaluate the Safety and Immunogenicity of Ad5-nCoV and Ad5-nCoV-IH in CoronaVac Immunized Children and Adolescents (clinicaltrials.gov) - P3 | N=1000 | Recruiting | Sponsor: CanSino Biologics Inc. | Not yet recruiting ➔ Recruiting | N=2000 ➔ 1000

Enrollment change • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Immunogenicity, Efficacy and Safety of Inhaled (IH) Viral Vectored Vaccine (Convidecia, CanSino) as Second Booster Dose Against Emerging Variants of Concern (VOC) (clinicaltrials.gov) - P3 | N=540 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Solid Tumor

Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) in Elderly Adults (clinicaltrials.gov) - P4 | N=300 | Completed | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine (clinicaltrials.gov) - P3 | N=1350 | Not yet recruiting | Sponsor: CanSino Biologics Inc.

New P3 trial • Infectious Disease • Novel Coronavirus Disease • IFNG